American Association for Cancer Research
00085472can122560-sup-tab2.pdf (48.04 kB)

Supplementary Table 2 from Autoantibody Signatures Involving Glycolysis and Splicesome Proteins Precede a Diagnosis of Breast Cancer among Postmenopausal Women

Download (48.04 kB)
journal contribution
posted on 2023-03-30, 22:00 authored by Jon J. Ladd, Timothy Chao, Melissa M. Johnson, Ji Qiu, Alice Chin, Rebecca Israel, Sharon J. Pitteri, Jianning Mao, Mei Wu, Lynn M. Amon, Martin McIntosh, Christopher Li, Ross Prentice, Nora Disis, Samir Hanash

PDF file - 48K, Peptide sequences from proteins identified in immune complexes.



We assessed the autoantibody repertoire of a mouse model engineered to develop breast cancer and the repertoire of autoantibodies in human plasmas collected at a preclinical time point and at the time of clinical diagnosis of breast cancer. In seeking to identify common pathways, networks, and protein families associated with the humoral response, we elucidated the dynamic nature of tumor antigens and autoantibody interactions. Lysate proteins from an immortalized cell line from a MMTV-neu mouse model and from MCF7 human breast cancers were spotted onto nitrocellulose microarrays and hybridized with mouse and human plasma samples, respectively. Immunoglobulin-based plasma immunoreactivity against glycolysis and spliceosome proteins was a predominant feature observed both in tumor-bearing mice and in prediagnostic human samples. Interestingly, autoantibody reactivity was more pronounced further away than closer to diagnosis. We provide evidence for dynamic changes in autoantibody reactivity with tumor development and progression that may depend, in part, on the extent of antigen–antibody interactions. Cancer Res; 73(5); 1502–13. ©2012 AACR.

Usage metrics

    Cancer Research



    Ref. manager